Support for Ofev® just keeps coming! Ofev® (nintedanib) was first approved by the U.S. FDA in 2014 for the treatment of idiopathic pulmonary fibrosis (IPF) after clinical trials, especially the INPULSIS…
Results from the Phase 3 CASTOR trial from Janssen Pharmaceutical Companies were recently released, finding that Darzalex (daratumumab) was extremely effective at reducing the risk of multiple myeloma progression or…
On May 23, 2017, a biopharmaceutical company, ChemoCentryx, Inc., made a huge announcement. Not only has the US Food and Drug Administration (FDA) granted orphan drug designation for their drug, avacopan,…
GW Pharmaceuticals sta scoprendo ... Epidiolex® (fabbricato e testato da GW Pharmaceuticals) è un candidato medico cannabinoide medico per il trattamento di sindromi di epilessia rara, resistente e precoce, come…
GW Pharmaceuticals découvre ... Epidiolex® (fabriqué et testé par GW Pharmaceuticals) est un candidat cannabinoïde médical leader pour le traitement de syndromes d'épilepsie rares, résistants et débutants tels que le…
De grandes nouvelles pour les patients atteints d'un cancer du sein métastatique muté par le BRCA: un traitement connu contre le cancer de l'ovaire a passé des essais cliniques de…
Aerie Pharmaceuticals announced exciting efficacy results from the second part of its Phase 3 clinical trial of Roclatan at the end of last month. Roclatan is devised for a group…
Notizie grandi per i pazienti con tumore metastatico mutato BRCA mutato: un trattamento con cancro ovarico conosciuto ha superato le sperimentazioni cliniche di fase III per il tumore metastatico mutato…
Want some more news, events and announcements on hemophilia? We got 'em! [one_half] [/one_half] [one_half_last] FDA Clears New Drug for Hemophilia B Treatment Virtual-reality Game Helps This Boy…
“If you half-ass something, you should only expect to get half an ass back.” This was the sort of lesson I learned from my dad. The moral is there, even…
On a beautiful summer day, a baby girl named Remi made her debut in the world. To all appearances, everything was normal—10 fingers, 10 toes, and bright eyes. Her parents…
Imagine being told that your son probably wouldn’t live beyond his twenties when he was only six years old. Unfathomable. But that’s the news the Vella family received and had…
If you were to rate the severity of different types of epilepsy from one to 10, 10 being the most severe, Dravet syndrome would be an 11. Dravet is catastrophic…
At a recent conference, Jazz Pharmaceuticals presented positive efficacy results from the JZP-110 (TONES) studies in adult patients with sleep impairment conditions and the excessive sleepiness associated with these diseases.…
For people living with Idiopathic Pulmonary Fibrosis (IPF), every day is part of an ongoing battle to hold on tight to lung function as long as possible. That battle can…
I came across an interesting blog about World Hemophilia Day (WHD) which was April 17th, 2017. It’s an interesting read, and fairly simple, one every woman should know about for inspiration,…
It’s more difficult to prove something to someone than we often imagine. Then again, there are also times when proving something that may or may not exist is relatively easy.…
Rhythm Pharmaceuticals is currently developing a melanocrotin-4 (MC4) receptor therapy called setmelanotide for the treatment of obesity and related disorders caused by genetic defects. This therapy could potentially be used to…
At the recent Annual American Society of Clinical Oncology (ASCO) Meeting, bluebird bio, Inc. released updated data from its Phase 1 trial of bb2121. bb2121 is a new anti-BCMA chimeric…
The highly-anticipated data from Pfizer's Phase 3 Octave Studies of tofacitinib in ulcerative colitis patients were published early last month in The New England Journal of Medicine. The data overall…
BioLineRx Ltd. announced in early May that following a successful meeting with the U.S. FDA, the initiation of a Phase 3 clinical trial for stem cell mobilization in multiple myeloma…
Celgene Corporation, partnered with Acceleron Pharma Inc., announced at the beginning of this month that target enrollment of myelodysplastic syndromes (MDS) and beta thalassemia patients for the MEDALIST and BELIEVE…
At the 53rd Annual Meeting of the American Society of Oncology at the beginning of June, Amgen presented promising data from the largest Phase 3 international multiple myeloma trial that…
Passion. Passion doesn’t persist. It is there, and then it is gone. Standing on the diving board is pre-passion. Falling toward the water is post-passion. It's the jump that's ripe with…
Aeglea BioTherapeutics recently provided an update concerning their clinical trial for arginase deficiency disorder. The four-word summary? They still need patients. Aeglea specializes in amino acid metabolism. Their focus is…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
